HCF2 Polyclonal Antibody, AbBy Fluor-647 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9843r-bf647 |
| Product Name | HCF2 Polyclonal Antibody, AbBy Fluor-647 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | AbBy Fluor-647 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human HCF2/Heparin Cofactor II |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 3053 |
| Synonyms | HC II; HCF2; HLS2; Leuserpin 2; LS2; Protease inhibitor leuserpin 2; SERPIND1; HEP2_HUMAN. |
| Background | The herpes simplex virus (HSV) infection is initiated by VP16, a viral transcription factor that activates the viral immediate-early (IE) genes.The anticoagulant action of heparin is dependent on plasma components termed heparin cofactors. The first of these to be well characterized was antithrombin III. Heparin Cofactor II is antigenically distinct from AT III. Heparin Cofactor II is normal in patients with AT III deficiency and is low in patients with disseminated intravascular coagulation. It is expressed predominantly in liver. Its function is: thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, Heparin Cofactor II becomes the predominant thrombin inhibitor in place of antithrombin III (AT III). Also inhibits chymotrypsin, but in a glycosaminoglycan independent manner and peptides at the N terminal of Heparin Cofactor II have chemotactic activity for both monocytes and neutrophils. The N terminal acidic repeat region mediates, in part, the glycosaminoglycan accelerated thrombin inhibition. Defects in SERPIND1 are the cause of Heparin Cofactor II deficiency. Heparin Cofactor II deficiency is an important risk factor for hereditary thrombophilia, a multifactorial trait characterized by recurrent thrombosis and abnormal platelet aggregation in response to various agents. Heparin Cofactor II deficiency is inherited as an autosomal dominant disorder, in which affected individuals are prone to develop serious spontaneous thrombosis. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
Frequently asked questions
Which applications is HCF2 Polyclonal Antibody, AbBy Fluor-647 Conjugated (bs-9843R-BF647) validated for, and at what dilution?
bs-9843R-BF647 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does HCF2 Polyclonal Antibody, AbBy Fluor-647 Conjugated (bs-9843R-BF647) react with?
Tested reactivity: Human, Mouse, Rat.
How should bs-9843R-BF647 be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise HCF2 Polyclonal Antibody, AbBy Fluor-647 Conjugated (bs-9843R-BF647)?
KLH conjugated synthetic peptide derived from human HCF2/Heparin Cofactor II
What are the excitation and emission wavelengths of the AbBy Fluor-647 conjugate (bs-9843R-BF647)?
AbBy Fluor-647 on bs-9843R-BF647: excitation / emission 650nm/665nm.